Value in Health

Papers
(The H4-Index of Value in Health is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?619
MSR47 Feasibility Assessment of Indirect Treatment Comparison of Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps543
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective116
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany99
HSD35 If Primary Prevention Is the Solution, Why Don't We Take Advantage of All Opportunities in Brazil?90
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK81
POSB179 Epidemiological Disease Burden of Heart Failure, Unspecified Based on Routinely Collected Health Insurance Claims Data67
POSC176 Is Pain Severity Associated with Functional Limitations Among United States Adults? A Cross-Sectional Study Using 2018 Medical Expenditure Panel Survey62
HPR146 Specialty Pharmacy Use and Adherence to Oral Anticancer Medications for Breast Cancer and Prostate Cancer: Implications for Medicare Part D Policy62
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing61
HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review59
PCR11 Understanding the Patient Experience of Erythropoietic Protoporphyria and X-Linked Protoporphyria: A Qualitative Study55
POSC173 The Association Between Physical Activity, Body Mass Index and Health Complaints Among Hungarian School-Aged Children55
HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment54
MSR93 A Systematic Review of Current Evidence and Gaps on the Impact of Oral Antipsychotic Treatments in Schizophrenia53
POSB213 Assessing the Changes of Hungarian Health Professional Workforce, Proportional to Population between 2003-201852
SA60 Seeking ISPOR Abstracts: Is Searching Embase Enough?49
EE198 Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Essential Hypertension in Chinese Setting48
POSB187 Study of Awareness of Pharmacy Employees in Ukraine with the Problem of Antibiotics Resistance47
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib44
PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States44
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome43
CO66 Real-World Study on Characteristics, Post-Nephrectomy Journey, and Outcomes of Patients with Early-Stage Renal Cell Carcinoma Based on Risk Groups41
EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan41
Author Reply40
POSC138 The Burden Due to Moderate-to-Severe Paediatric Atopic Dermatitis Treated with Systemic Immunosuppressants on the Healthcare System in England40
Editorial Board38
EE190 Association of Total Annual Costs of Duchenne Muscular Dystrophy With Disease Severity38
MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods37
POSB225 Differences and Similarities in the Methods: of Pricing of Prescription Drugs in Bulgaria, France, Germany, Belgium, and the UK: A Comparative Analysis37
MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making37
PCR101 Item Response Theory Analysis of the Ilqi37
HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany35
POSB231 How to Determine Surgical Pathway Operating Costs in Chronic Rhinosinusitis with Nasal Polyposis Patients? The Time Driven Activity-Based Costing Experiment34
0.12958812713623